The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes

British Journal of Haematology

Volumn 115, Issue 4, 2001, Pages 881-894

  Zorat, Francesca ^a   Shetty, Vilasini ^a   Dutt, Diya ^a   Lisak, Laurie ^a   Nascimben, Fabiana ^a   Allampallam, Krishnan ^a   Dar, Saleem ^a   York, Aaron ^a   Gezer, Sefer ^a   Venugopal, Parameswaran ^a   Raza, Azra ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Myelodysplastic syndromes; Thalidomide; Transforming growth factor beta; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD LEVEL; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEMOGLOBIN DETERMINATION; HUMAN; MACROPHAGE; MICROVASCULATURE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REMISSION; THROMBOCYTE COUNT;

AGED; CASE-CONTROL STUDIES; CYTOKINES; ENDOTHELIAL GROWTH FACTORS; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOKINES; MALE; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; REMISSION INDUCTION; THALIDOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035669269     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03204.x     Document Type: Article

References (53)

1. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes
2. Angiogenesis: Mechanistic insights, neovascular disease, and therapeutic prospects
3. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
4. Proposal for the classification of myelodysplastic syndromes
5. Topotecan in the treatment of hematologic malignancies
6. Prognostic relevance of microvessel density in cancer of the urinary bladder
7. Report of an international working group to standardize response criteria for myelodysplastic syndromes
8. Thalidomide is an inhibitor of angiogenesis
9. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndromes in patients 55-66 years of age
10. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (AML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment in Cancer (EORTC-LCG)
11. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis?
12. Treatment of high risk myelodysplastic syndrome with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF)
13. Angiogenesis in cancer, vascular, rheumatoid arthritis and other diseases
14. Tumor angiogenesis
15. Treatment of myelodysplastic syndrome with hematopoietic growth factors
16. A. Role for tumor necrosis factor a, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndromes
17. Intratumoral angiogenesis: A new prognostic indicator for stage I endometrial adenocarcinomas?
18. Biologic characteristics of patients with hypocellular myelodysplastic syndromes
19. International scoring system for evaluating prognosis in myelodysplastic syndromes
20. Thalidomide on the comeback trail
21. Immunosuppressive properties of thalidomide. Inhibition of lymphocyte proliferation alone and in combination with cyclosporin or FK506
22. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
23. Overexpression of tumor necrosis factor (TNF) alpha and interferon (IFN) gamma by bone marrow cells from patients with myelodysplastic syndromes
24. Randomized study of 13-cis retinoic acid vs placebo in myelodysplastic disorders
25. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndromes
26. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
27. Differentiation therapy in myelodysplastic syndromes
28. Two in situ techniques do not differentiate between apoptosis and necrosis but rather reveal distinct patterns of DNA fragmentation in apoptosis
29. Indication of an involvement of interleukin 1-beta converting enzyme (ICE)-like protease in intramedullary apoptotic cell death in the bone marrows of patients with myelodysplastic syndromes (MDS)
30. Treatment of anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin
31. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
32. Angiogenesis in myelodysplastic syndrome
33. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
34. Anti-TNF therapies in rheumatoid arthritis Crohn's disease, sepsis and myelodysplastic syndromes
35. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndrome
36. Novelinsights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines
37. Pilot study of pentoxifylline and ciprofloxacin with or without dexamethasone produce encouraging results in myelodysplastic syndrome
38. Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS)
39. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
40. Thalidomide produces transfusion independence in long-standing refractory anaemias of patients with myelodysplastic syndromes
41. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin lymphoma. An immunohistochemical and ultrastructural study
42. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
43. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes
44. Anti-tumor activity of thalidomide in refractory multiple myeloma
45. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer
46. Binding of thalidomide to 1-acid-glycoprotein may be involved in its inhibition of TNF production
47. Bone marrow angiogenesis and progression in multiple myeloma
48. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies
49. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
50. Measurement of serum cytokine levels in patients with myelodysplastic syndromes
51. Apoptosis and its significance in MDS; controversies revisited
52. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome
53. Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes